Current Evidence of Neuroprotection in TAVR

Research output: Chapter/Conference proceedingChapterAcademic

Abstract

Stroke rate after transcatheter aortic valve replacement (TAVR) is currently approximately 2-3%, and strokes have a tremendous impact on patients' quality of life. Embolic protection devices may possibly reduce the number of strokes, but randomized data proving that is currently lacking. Histopathological studies with filter-based devices demonstrate capture of embolized debris in almost all patients, which may suggest that these devices may stop embolized particles from reaching the brain. Imaging studies show brain injury in the vast majority after TAVR as well; however, not all of them lead to clinical symptoms. The impact of these silent lesions is not fully understood but is thought not to be trivial as these lesions are linked to early neurocognitive decline. This chapter will discuss the mechanism and clinical impact of stroke after TAVR, current available embolic protection devices, histopathological characteristics of captured debris, and available evidence of neuroprotection in TAVR.

Original languageEnglish
Title of host publicationMastering Structural Heart Disease
PublisherJohn Wiley & Sons Inc.
Chapter21
Pages163-168
Number of pages6
ISBN (Electronic)9781119807841
ISBN (Print)9781119807827
DOIs
Publication statusPublished - 27 Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 John Wiley & Sons Ltd. All rights reserved.

Fingerprint

Dive into the research topics of 'Current Evidence of Neuroprotection in TAVR'. Together they form a unique fingerprint.

Cite this